tiprankstipranks
Advertisement
Advertisement

JP:4569 Stock Latest News

KYORIN to Promote World’s First Cream Treatment for Allergic Conjunctivitis in Partnership with Santen
Company AnnouncementsKYORIN to Promote World’s First Cream Treatment for Allergic Conjunctivitis in Partnership with Santen
3d ago
4569
KYORIN Pharmaceutical Details Q1 Results and Pipeline Outlook for FY2027
PremiumCompany Announcements
KYORIN Pharmaceutical Details Q1 Results and Pipeline Outlook for FY2027
7d ago
4569
KYORIN Pharmaceutical Warns of Profit Slump and Dividend Cut Despite Strong Balance Sheet
PremiumCompany Announcements
KYORIN Pharmaceutical Warns of Profit Slump and Dividend Cut Despite Strong Balance Sheet
7d ago
4569
KYORIN, Santen Team Up to Expand Marketing of Novel Allergic Conjunctivitis Cream in Japan
PremiumCompany Announcements
KYORIN, Santen Team Up to Expand Marketing of Novel Allergic Conjunctivitis Cream in Japan
24d ago
4569
KYORIN Pharmaceutical Keeps Annual Dividend Steady at ¥57 Per Share
PremiumCompany Announcements
KYORIN Pharmaceutical Keeps Annual Dividend Steady at ¥57 Per Share
3M ago
4569
KYORIN Expands Performance-Linked Stock Compensation Plan to Corporate Officers
PremiumCompany AnnouncementsKYORIN Expands Performance-Linked Stock Compensation Plan to Corporate Officers
3M ago
4569
KYORIN Pharmaceutical Reshapes Board and Audit Team in June Leadership Overhaul
Premium
Company Announcements
KYORIN Pharmaceutical Reshapes Board and Audit Team in June Leadership Overhaul
3M ago
4569
KYORIN Sets Aggressive Investment Plan in New Medium-Term Strategy “Vision 110 – Stage 2 –”
Premium
Company Announcements
KYORIN Sets Aggressive Investment Plan in New Medium-Term Strategy “Vision 110 – Stage 2 –”
3M ago
4569
KYORIN Pharmaceutical Misses Interim Profit Forecasts on Weaker Sales and Higher R&D Costs
PremiumCompany Announcements
KYORIN Pharmaceutical Misses Interim Profit Forecasts on Weaker Sales and Higher R&D Costs
3M ago
4569
KYORIN Pharmaceutical Announces Consolidated Results and Outlook for FY2025
PremiumCompany Announcements
KYORIN Pharmaceutical Announces Consolidated Results and Outlook for FY2025
3M ago
4569
Kyorin Pharmaceutical Slashes Profit Outlook and Plans Dividend Cut After Sharp Earnings Decline
PremiumCompany Announcements
Kyorin Pharmaceutical Slashes Profit Outlook and Plans Dividend Cut After Sharp Earnings Decline
3M ago
4569
Kyorin to Transfer Generic Drug Operations to Co-Creation Platform with Daito
PremiumCompany Announcements
Kyorin to Transfer Generic Drug Operations to Co-Creation Platform with Daito
3M ago
4569
KYORIN Licenses BIODOL’s Novel Neuropathic Pain Drug for Key Asian Markets
PremiumCompany AnnouncementsKYORIN Licenses BIODOL’s Novel Neuropathic Pain Drug for Key Asian Markets
4M ago
4569
KYORIN Secures Exclusive Japan Rights to Promote and Distribute J&J’s SIRTURO
Premium
Company Announcements
KYORIN Secures Exclusive Japan Rights to Promote and Distribute J&J’s SIRTURO
4M ago
4569
Kyorin Pharma Overhauls Governance With New Mandate-Based Officer System
Premium
Company Announcements
Kyorin Pharma Overhauls Governance With New Mandate-Based Officer System
5M ago
4569
KYORIN Wins Approval for Faster, More Sensitive GeneSoC FluA/B Influenza Test Kit
PremiumCompany Announcements
KYORIN Wins Approval for Faster, More Sensitive GeneSoC FluA/B Influenza Test Kit
6M ago
4569
KYORIN Pharma Releases Nine-Month Consolidated Results and Outlook
PremiumCompany Announcements
KYORIN Pharma Releases Nine-Month Consolidated Results and Outlook
6M ago
4569
KYORIN Pharmaceutical Lifts Nine-Month Profit but Keeps Lower Full-Year Outlook
PremiumCompany Announcements
KYORIN Pharmaceutical Lifts Nine-Month Profit but Keeps Lower Full-Year Outlook
6M ago
4569
KYORIN Taps Lunatus to Launch Antibacterial Drug Lasvic Across Middle East
PremiumCompany Announcements
KYORIN Taps Lunatus to Launch Antibacterial Drug Lasvic Across Middle East
7M ago
4569
KYORIN Pharmaceutical Reports Mixed Financial Results for H1 2025
PremiumCompany AnnouncementsKYORIN Pharmaceutical Reports Mixed Financial Results for H1 2025
9M ago
4569
KYORIN Partners with Hinge Bio for SLE Drug Development in Japan
Premium
Company Announcements
KYORIN Partners with Hinge Bio for SLE Drug Development in Japan
10M ago
4569
KYORIN Pharma Announces Phase 3 Study Results for Pulmonary Sarcoidosis Treatment
Premium
Company Announcements
KYORIN Pharma Announces Phase 3 Study Results for Pulmonary Sarcoidosis Treatment
11M ago
4569

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >